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Summary 
Background  
Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults 
and leads to severe fatigue, significant physical functional impairment, and restricted social 
participation. In this study, we aimed to determine whether cognitive behavioural  therapy 
(CBT) optionally combined with graded exercise compared to standard care alone improved 
the health status of patients with DM1.  
Methods 
In this, prospective 16-month trial, we randomly assigned in a 1:1 ratio, 255 severely fatigued 
adult DM1 patients to CBT compared to standard care. We defined severe fatigue as a score 
of ≥35 on the checklist individual strength, subscale fatigue severity (CIS-fatigue). Patients 
were recruited at four neuromuscular referral centres - with experience in treating DM1 
patients - located in Paris, France, Munich, Germany, Nijmegen, the Netherlands and 
Newcastle, the United Kingdom. Randomisation was performed by local trial staff via a 
central, GCP-compliant, web-based system, developed by the Tayside Clinical Trials Unit. 
CBT focused on addressing reduced initiative, increasing physical activity, optimizing 
interaction with significant others, regulating sleep-wake pattern, addressing pain behaviours 
and beliefs and beliefs about fatigue and DM1. CBT was delivered by experienced and 
specifically trained CBT therapists over a 10-month period in 10-14 sessions, with the 
majority of session given in the first four to five months. A physical therapist supervised 
graded exercise module aimed at increasing physical fitness could be added to CBT, in two 
of the study centres. The primary end point was 10-month change on the DM1-Activ-c scale, 
a disease-specific Rasch-built measure of capacity for activity and social participation that 
has a 0-100 interval range.  Only outcome adjudicators were blind to treatment allocation. 
Statistical analysis of primary outcome of change in DM1-Activ-c score was intention-to-treat, 
utilising mixed effects linear regression models with baseline as a covariate. 
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Findings 
255 patients were randomised between April 2014 and May 2015, 128 to the intervention 
and 127 to standard care alone. At 10 months, the adjusted mean DM1-Activ-c score in the 
intervention group had improved 1·53 points (95% CI -0·14 to 3·20) and had worsened 2·02 
(-4·02 to -0·01) points in the standard care group, with a mean difference in favour of the 
intervention groupof 3.27 points (0·93 to 5·62, p = 0·007). We recorded 244 and 155 adverse 
events (AE); and 24 and 23 serious adverse events (SAE) in the intervention and standard 
care groups, respectively. AE and SAE were distributed equally across groups, with the 
exception of falls occurring more frequently in the intervention group compared to the 
standard care group, 160 versus 72 falls, respectively. In the intervention group, 5 falls 
classified as SAE versus 1 in the standard care group. Most frequently occurring non-fall AE 
and SAE involved cardiac, pulmonary-thoracic or gastro-intestinal systems, and were in the 
latter two often of infectious nature. 
Interpretation 
CBT increased the capacity for activity and social participation in DM1 patients at 10 months. 
With no curative and few symptomatic treatments available, CBT could be considered for use 
in severely fatigued DM1 patients. 
Funding 
Funded by the European Union Seventh Framework Program, under grant agreement 
number 305697 (OPTIMISTIC project); Clinicaltrials.gov number, NCT02118779.  
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Background 
Myotonic dystrophy type 1 (DM1) is an autosomal dominant chronic progressive multi-system 
disorder and the most common form of muscular dystrophy in adults.1 The disease leads to 
significant physical impairment, which in combination with the neuropsychological impacts of 
the condition, results in severely restricted social participation.2-6 No curative treatment 
exists, and evidence for the efficacy of rehabilitative approaches is largely lacking, resulting 
in considerable unmet need for treatment that aims to improve health status.7 
A DM1-specific model of factors determining health status was empirically derived from the 
findings of our longitudinal study.8 This model predicts that improvement of patient reported 
health status can be achieved by addressing reduced initiative, optimizing physical activity, 
and alleviating experienced fatigue. Previous studies have shown that fatigue is a highly 
prevalent and debilitating symptom in DM1.9,10 Cognitive behavioural therapy (CBT) has 
been found effective in relieving fatigue in chronic fatigue syndrome and type 1 diabetes.11,12 
In facioscapulohumeral muscular dystrophy, CBT reduced fatigue and increased objective 
activity (as measured with actometry) and social participation.13 In addition, there is 
accumulating evidence supporting the beneficial effects of low-to-moderate-intensity strength 
and aerobic exercise training and an active lifestyle in neuromuscular diseases.14,15 
Nevertheless, recent reviews conclude that studies evaluating graded activity in 
neuromuscular diseases are limited in number and quality, and that there is a need for 
disease-specific, randomised, controlled trials investigating the effect on health status.14,16 
We therefore conducted a large international, multi-center, randomised trial to determine 
whether CBT plus optional graded exercise improved health status of patients with DM1 
compared to standard care alone.17  
Methods 
Study design and participants 
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Four European clinical sites (Munich, Germany; Nijmegen, the Netherlands; Newcastle, UK; 
Paris, France) collaborated in this study. Eligible patients with a confirmed genetic DM1 
diagnosis who provided written informed consent were randomly assigned to study groups. 
There were up to five assessment visits: eligibility screening followed by baseline, five, 10 
and 16 months post-randomisation, with the primary outcome being measured at 10 months. 
The study protocol has previously been published.17  
We recruited DM1 patients aged 18 years and older who were severely fatigued as 
measured by the checklist-individual strength subscale fatigue (CIS-fatigue, score ≥35)18, 
able to walk independently (walking aids permitted) and undergo trial interventions (Table S1 
in the Web Extra material, available at thelancet.com). The study was approved by the 
institutional review boards at each of the four clinical sites and conducted in accordance with 
the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. Patients 
were recruited by invitation via DM1 registries, from clinics via their treating neurologists, or 
independently through study awareness by patient organizations. We invited the patients’ 
caregiver to participate, as described previously.17 
Randomisation and masking 
Eligible patients were randomised in a 1:1 ratio via a central, GCP-compliant web-based 
system called the Tayside Randomisation System (TRuST) developed by the Tayside 
Clinical Trials Unit at the University of Dundee, UK. Trials Unit statisticians and data 
management staff programmed TRuST to implement the randomisation described in the 
OPTIMISTIC protocol namely that randomisation was stratified by site (location of inclusion) 
and minimized for baseline DM1 severity (as assessed by the muscular impairment rating 
scale (MIRS)) and for baseline involvement of a caregiver.19 Immediate family members (i.e 
parents, children, siblings) were allocated as a cluster to avoid treatment contamination.  
Only outcome adjudicators were blind to treatment allocation, patients could not be blinded to 
allocation. Outcome adjudicators were instructed to refrain from interactions with the patient 
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that could disclose treatment allocation. During therapy, patients were discouraged from 
disclosing their treatment allocation to outcome adjudicators. 
Study procedures and interventions    
Patients in the comparison group received standard care applicable to each individual’s 
country (table S2 in the Web Extra material). In addition to receiving standard care, all 
patients randomised to the intervention arm also received CBT (details in table S3 in the 
Web Extra material).17 In a process of shared-decision making on the basis of therapist 
assessment and questionnaire evaluation, CBT was customized to the individual participant 
by the selection of one or more appropriate treatment modules: regulating sleep-wake 
pattern, compensating for a reduced initiative, formulating helpful beliefs about fatigue and 
DM1, optimizing social interactions and coping with pain. In addition, CBT included a graded 
activity module for every patient. To ensure a high degree of treatment integrity, CBT was 
manual-based, delivered by experienced CBT therapists with extensive training prior to start 
of the trial, and monitored during the delivery of the intervention (table S3). The treatment 
manual is available upon request (see table S3 for details). We evaluated treatment integrity 
of CBT as given during the conduct of the trial by means of evaluation of therapist-recorded 
case report forms from each session from every CBT participant, and by the assessment of 
audio records of CBT sessions that were recorded during the intervention (details in Web 
Extra material, S8).  
If considered appropriate through a process of shared-decision making between CBT 
therapist and participant, a graded exercise module supervised by a physical therapist could 
optionally be added to CBT in the participants randomised to intervention (table S4 in the 
Web Extra material). Although we planned this in all four centres, differences in standard 
care meant we could implement the graded exercise in two out of four sites (Nijmegen and 
Newcastle). As it was not possible to offer the graded exercise module as an option within 
the French and German care pathways for DM1 patients, this constituted a protocol 
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deviation, as listed in the Web Extra material. The graded exercise module constitutes a 
structured exercise program aimed at increasing physical fitness. The program was 
individually defined, but targeted incorporating moderate intensity exercises (e.g. walking, 
cycling, jogging or dancing) for at least half an hour, three times a week. The graded 
exercise module was given during the intervention period. The overall intervention (i.e. CBT 
and GET when applicable) was scheduled for a duration of 10 months, starting directly after 
randomisation. Patients were to receive 10-14 sessions of CBT (no specific duration 
specified), with the majority delivered in the first 4-5 months. We planned for a minimum of 5 
face-to-face sessions, but other communication formats, such as telephone or video calls 
were acceptable. 
Onsite and remote visits to assess protocol compliance and adherence to good clinical 
practice  guidelines were performed during the conduct of the study by local trial staff and by 
staff from the coordinating Trials Unit in Dundee, United Kingdom. 
Outcomes measures 
The primary outcome was the change in DM1-Activ-c at the end of the 10-month intervention 
period (Web Extra material, table S5). The Rasch-built DM1-Activ-c is a DM1 specific patient-
reported outcome measure of capacity for activity and social participation.20,21 The DM1-
Activ-c with a 0-100 score range is the updated version of the DM1-Activ scale that had a 0-
40 score range. We based our power calculation on the DM1-Activ and planned it to be the 
primary outcome measure. However, deviating from the study protocol (Web Extra – list of 
protocol deviations), we decided to use the DM1-Activ-c after criticism of the DM1-Activ had 
led to the publication of an updated version that was available to us before the start of the 
study.21 
Predefined secondary outcome measures categorized into five groups were collected: 
physical activity and exercise capacity: six-minute walk test (6MWT) with Borg scale 
assessment, myotonic dystrophy health index (MDHI), physical activity measured with an 
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accelerometer (Web Extra S9); fatigue and sleepiness: fatigue and daytime sleepiness scale 
(FDSS), CIS-fatigue; quality of life: individualised neuromuscular quality of life questionnaire 
(InQoL); depressive symptoms: Beck-depression inventory-fast screen (BDI-fs) ;and 
cognition: Apathy evaluation scale – clinician version (AES-c) and Stroop test interference 
score (Table S5 and study protocol paper).17 The Borg scale is a subjective measure of 
perceived exertion taken immediately after the 6MWT; we utilised the 0-10 scale, as 
recommended previously.22 For accelerometry, we calculated mean 24h activity levels, and 
levels of activity during the 5 most active and 5 least active hours of the day. Adverse events 
(AE) and serious adverse events were reported continuously during the study and reviewed 
at each study visit.17 
Statistical analysis 
The agreed statistical analysis plan (SAP) was made publicly available at www.optimistic-
dm.eu prior to completion of the study (available from: www.optimistic-dm.eu: 
http://www.optimistic-dm.eu/images/com_projectfork/progress/OPTIMISTIC_SAP.pdf). 
Analyses were done by the trial statistician (A.H.), and checked by a second statistician 
(P.T.D). Based on a minimum clinically important mean difference of 1.4 on the 40-item 
DM1-Activ scale, a standard deviation of 3.5, effect size = 0.4, 80% power at the 5% 
significance level, a total sample size of 200 patients was required.17 We accounted for the 
potential of clustering of DM1 family members in identical treatment arms by inflating the 
sample size to 208. The trial was also fully powered for 6MWT, a secondary outcome 
assessing exercise capacity.23 The recruitment target was set at 296 to allow for a potential 
drop-out rate of up to 30% based on previous pilot studies in DM1 patients.24 Full details of 
the sample size calculations have been described previously (see full trial protocol and 
SAP).17 
The primary outcome analysis was conducted according to the principles of intention-to-treat 
as outlined on the ICH E9 ‘Statistical Principles for Clinical Trials’. We utilized mixed effects 
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regression models with baseline scores as a covariate to assess the change in DM1-Activ-c 
score at 10 months. Priorly, the raw sum scores of the DM1-Activ-c scale were translated 
into a log-odds units (logit) scale, using the Rasch-model.25 Since logits are difficult to 
interpret intuitively, the logits were converted into a centile metric score with values ranging 
from 0 (most severe activity and social participation limitations) to 100 (no activity and social 
participation limitations). The mixed effects models included the intervention (as a binary 
variable), age and the minimisation variables (MIRS score and involvement of the caregiver 
at baseline (as a binary variable) as fixed effects and site as random effect. Random effects 
were included for each subject in the repeated measures analyses, as well as for correlation 
within family group. Results are presented as model-derived means and 95% CIs. Planned 
subgroup analyses were carried out by testing for a subgroup by intervention interaction, as 
detailed previously (SAP).17 Predefined subgroups were implemented for number of CBT 
sessions attended, clinical site, severity of DM1 as defined by MIRS score, involvement of 
the caregiver, age, sex, and addition of the graded exercise module to CBT. All these 
analyses were repeated for all the secondary outcome measures. In addition, we performed 
post-hoc repeated measures analysis for primary and secondary outcomes at all timepoints. 
We used SAS software (version 9.4, SAS Institute Inc., Cary, NC, USA) for statistical 
analyses. 
Role of the funding source 
The funder of this trial had no role in the study design, data collection, analysis, interpretation 
of data, writing the report, or decisions regarding when to submit publications. All authors 
were involved in design and/or conduct of the study and in the preparation of the manuscript. 
All authors had full access to all data in the study and all authors take full responsibility for 
the decision to submit the paper for publication. They attest to the accuracy, completeness of 
the data and analyses.  Researchers wishing to get access to the data collected in the 
OPTIMISTIC study are requested to contact the last author at 
Baziel.vanEngelen@Radboudumc.nl and sign a data access agreement. Requests for 
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access will be reviewed by a panel consisting of one representative of the 4 clinical sites 
each, chaired by Baziel van Engelen. 
Results 
Study patients 
Patients were randomised between April 2, 2014 and May 29, 2015, with follow-up 
continuing until October 17, 2016 when the last patient underwent the 16-month assessment. 
A total of 255 patients underwent randomisation, 128 patients were allocated to the 
intervention and 127 allocated to standard care alone (Figure 1). Baseline characteristics 
between both groups were similar (Table 1). Thirty-three out of the 128 (26%) patients 
randomised to intervention were involved in the additional graded exercise module. There 
was no cross-over from standard care to intervention; four patients randomised to CBT 
considered it too much burden and did not attend any sessions, but remained in the trial. At 
10 months, 231 (91%) patients completed the primary outcome evaluation, with similar 
losses to follow-up across both groups. By the end of the study at 16 months, 225 (88%) 
patients remained in the trial, with a total of 14 formal withdrawals in the intervention group 
and 16 in the standard care group. The reasons given for trial withdrawal included the burden 
of travelling to clinical site for trial measurements and the number of questionnaires to be 
completed at each visit. 
Protocol deviations 
During the conduct of the study, some protocol violations occurred; these are listed in the 
Web Extra Material available at thelancetneurology.com. Most importantly, we made use of 
DM1-Activ-c scale, an updated version of the DM1-Activ scale. Whereas the original scale 
DM1-Activ was published in 2010, criticism led to its revision and publication of an updated 
version in 2015.20,21 As DM1-Activ-c was available before inclusion of the first patient, this 
updated version was used in the trial.21 In addition, although we planned to offer graded 
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exercise in all centres, we were only able to provide graded exercise in Nijmegen and 
Newcastle, thus limiting the availability of this add-on to CBT. Other deviations that occurred 
are listed in the Web Extra material. 
Primary and secondary outcomes 
After 10 months, the DM1-Activ-c scale, demonstrated an adjusted mean increase of 1·53 
(95%CI: -0.14 to 3.20) points in the CBT group compared with an adjusted mean decrease of 
2·02 (95%CI: -4.02 to -1.01) points in the standard care group (Table 2). In our predefined 
primary outcome analysis of DM1-Activ-c, there was a difference between both groups of 
3·27 points (95%CI: 0·93 to 5·62, p = 0·007) in favour of the intervention group at 10 months. 
Differences at 10 months in favour of CBT were also found for total distance on 6MWT, the 
fatigue and daytime sleepiness scale (FDSS), CIS-fatigue and daily activity levels (24 hours 
and most active 5 hours, average of seven consecutive days) measured by accelerometry 
(Table 2). Although MDHI and InQoL-quality of life scores decreased from baseline to 10 
month follow-up in the intervention and standard care group, no significant between-group 
differences were found. Three secondary outcomes measures (i.e. apathy evaluation scale, 
Stroop interference, BDI-FS), demonstated no change over time and no between-group 
differences (Table 2).  
With one exception (i.e. the effect of site on FDSS at 10 months), pre-specified subgroup 
analyses yielded no significant interactions of age, sex, site, MIRS, involvement of caregiver, 
number of CBT sessions or the addition of a supervised graded exercise module to CBT on 
primary or secondary outcomes at 10 months, after Bonferroni correction for multiple testing 
(Web Extra tables S6a and S6b). In a post-hoc analysis, scores on the CIS-fatigue scale at 
10 months had decreased to <35 in 47 out of 112 (42%) and 20 out of 106 (19%) patients in 
the intervention and standard care groups, respectively. 
For DM1-Activ-c, post-hoc repeated measures analysis demonstrated improved scores 
compared to baseline in the intervention group at five months, maximizing at 10 months and 
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continuing until 16 months, although there was a drift towards the standard care group 
scores at 16 months (Web Extra table S7). The difference between intervention and standard 
care groups over all time periods was in favour of the intervention (p = 0·004). Similar 
temporal patterns were seen for 6MWT, MDHI, FDSS, CIS-fatigue, accelerometry (mean 24 
hours and highest 5 hours of activity) and InQoL (quality of life domain) (Web Extra table S7). 
Of these, 6MWT, FDSS, CIS-fatigue and accelerometry demonstrated significant between-
group differences. BDI-fs and AES-c scores were relatively stable across timepoints and we 
detected no significant between-group differences. Although Stroop interference scores 
improved with time in both groups, no between-group differences were found (Web Extra 
table S7). 
Adverse events  
We recorded a total of 399 adverse events (AE) in 128 subjects, with 244 events in 65 
patients in the intervention group compared to 155 events in 63 patients in the standard care 
group (Table 3). A total of 226 (56·6%) AE were related to falls, 155 in the intervention and 
71 in the standard care group. 51 AE (12·8%) were related to infections and infestations, 32 
in the intervention versus 19 in the standard care group (table 3), these AE comprised mostly 
upper respiratory tract infections, influenza and infections in the oral cavity. We recorded 5 
and 12 AE related to the respiratory tract, thorax and mediastinum, in intervention and 
standard care group, respectively. All other AEs were distributed equally between groups 
(table 3). A total of 47 serious adverse events (SAE) occurred in 34 patients during the 
conduct of the study (Table 4). SAE occurred with similar frequency in the intervention group 
and the standard care group; 24 versus 23 events in 19 and 15 patients, respectively. 
Distribution of SAE across both groups was similar, with the exception of SAE related to falls, 
which occurred more frequently in the intervention group (five versus one). 
Discussion 
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The multi-system and progressive nature of DM1 leads to severe physical impairment, 
restricted social participation and premature death, yet no FDA approved therapies are 
available.3,26-28 Experienced fatigue is a highly prevalent and debilitating symptom that has 
been shown to have the greatest impact on the lives of patients with DM1.10 Data from this 
prospective trial, in which severely fatigued adult DM1 patients were randomly assigned to 
CBT compared to standard care, show that CBT by month 10 increased capacity for activity 
and participation as measured with the DM1-Activ-c scale. In addition, CBT was superior to 
standard care on several secondary outcome measures of experienced fatigue (CIS-fatigue 
and FDSS), exercise capacity (6MWT), and objective physical activity as measured with 
accelerometry. At 10 months, improvements in outcome measures for quality of life (InQoL – 
quality of life subdomain) and disease burden (MDHI) were not significantly different between 
groups. It should be noted the trial was not powered for any of the secondary outcome 
measures except the 6MWT.  
In DM1, few, if any fully validated disease-specific outcome measures exist, complicating the 
conduction of clinical trials in DM1.29 The sensitivity to change for DM1-specific outcome 
measures, including the DM1-Activ-c scale, was unknown during the design phase of the 
trial. Nonetheless, we selected the best outcome measures available at that time, after 
careful consideration in our consortium and based on consensus literature in the international 
DM1 community.30 We think the clinical relevance of a 3·27 point difference on the DM1-
Activ-c at 10 months, is supported by concurrent changes in the secondary outcome 
measures in favour of the intervention group that measured activity, exercise capacity, and 
fatigue. In particular, the 26·5 meter difference between groups at 6MWT at 10 months would 
be beyond the minimal clinically important change in DM1, which was previously defined as a 
6% change in walking distance between assessments.23 In the intervention group alone, the 
increase in walking distance from 389 to 421 meters means an increase of approximately 
8%. The outcomes at follow-up showed a tendency for a decrease of the beneficial effects of 
CBT over time. We suggest that booster sessions of CBT may help to maintain beneficial 
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effects to their maximum.31 Intriguingly, despite the increase in activity and exercise capacity, 
our study did not demonstrate changed levels of apathy. This may be explained by the 
nature of the CBT module dealing with apathy, in which we aimed to teach patients how to 
compensate for reduced initiative (but did not aim to increase levels of initiative per se). 
Subgroup analysis demonstrated that treatment effects were largely independent of age, sex, 
clinical site, the addition of a graded exercise supervised by a physical therapist, MIRS score 
at study entry or involvement of a caregiver. This means that despite differences in health-
care systems, favourable effects can be achieved in different settings. The lack of additive 
benefit with the addition of the graded exercise module means that CBT alone is capable of 
increasing activity levels and exercise capacity in DM1 patients. However, it should be noted 
that the group of patients that were involved with the graded exercise module was relatively 
small, which means care is needed when interpreting this result. Moreover, our results do not 
at all preclude a beneficial effect of exercise therapy per se (i.e. without CBT) in DM1 
patients, that was suggested in previous literature.32,33 Finally, we are suprised to find that the 
involvement of a caregiver with the study did not affect outcome, as we had expected better 
outcomes through supportive effects when caregivers were involved with the study.  
With regards to CBT safety, the equal distribution of SAE across groups is reassuring. 
However, falls were more frequent in the intervention group. Falls are a common 
complication in natural DM1 history, but the increased risk of less serious falls linked to the 
intervention underlines the importance of monitoring and where possible addressing this 
issue in clinical practice and future clinical trials.34,35 Furthermore, patients may underreport 
DM1 related complications, such as falls, as a result of reduced disease awareness.36 The 
excess fall frequency in the CBT group might be partly explained by a better recall resulting 
from more frequent contacts with trial staff (i.e. CBT therapists). Another explanation is a true 
increase in fall frequency as a result of spending more time being active, during which time a 
higher number of falls may occur. Other factors that we did not evaluate, such as the 
occurence of cataracts, may have influenced our results. It should be noted that the total 
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number of falls (i.e. 226) recorded in our study is relatively low in comparison with the recent 
Swedish study reporting falls in DM1 (which reported more than 200 falls occuring over a 1 
year period in 43 DM1 patients). This could be due to differences in fall evaluation and the 
fact that less severely affected patients (as defined by MIRS score) were excluded from the 
other study.35 Nevertheless, it seems reasonable to conclude that increasing activity levels in 
people with DM1 will lead to more falls, though most are minor.  Balancing this potential 
harm against the potential benefit of increased activity levels needs to be a shared decision 
between patient, carers and health professionals.  
This trial was characterized by high recruitment and low drop-out rates, in contrast to a 
previous study in this patient population.24 The selection of severely fatigued DM1 patients 
increases the generalisability of our results, as a previous study found severe fatigue in 74% 
of otherwise unselected DM1 patients, using the same instrument and cut-off score (i.e. CIS-
fatigue ≥35).9   
The trial has some limitations. The lack of information on respiratory muscle involvement can 
be considered a limitation of our study, as this may influence fatigue, physical activity and 
exercise capacity. Possibly, more frequent contact with trial staff for patients in the 
intervention group might have led to desirability bias: more desirable answers on patient-
reported outcome measures in comparison with the standard care group. Nevertheless, the 
statistically significant differences on objective physical activity, as measured with 
accelerometry and the six-minute walk test, a measure of exercise capacity, argue against 
desirability bias as a sole explanation for our favourable results. In common with other 
studies employing accelerometry, there were missing data.37,38 However, the quantity of 
missing data did not differ significantly between groups; with comparable reasons of 
noncompliance and device loss or failure, to those reported in the literature.37,38  
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Figure 1. Screening, randomisation, treatment, and follow-up in the trial 
Abbreviations: CIS-fatigue: checklist individual strength, subscale fatigue 
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Table 1. Characteristics of patients at study entry 
Characteristic* Intervention group 
(N = 128) 
Standard care group 
(N = 127) 
Clinical characteristics 
Age in years - mean 44·8 ± 11·7 46·4 ± 11·3 
Sex male/female – no. (%) 70 / 58 (55% / 45%) 67 / 60 (53% / 47%) 
BMI in kg/m2 26·5 ± 6·1 26·2 ± 5·3 
Age at disease onset in years 24·9 ± 12·6 26·2 ± 13·3 
Duration of disease in years 19·7 ± 9·6 19·4 ± 10·5 
Participants with a family member in the study 
– no. (%) 
12 (9%) 18 (14%) 
Location of enrollment – no (%) 
- Paris, France 
- Munich, Germany 
- Newcastle, United Kingdom 
- Nijmegen, the Netherlands 
 
37 (29%) 
33 (26%) 
25 (20%) 
33 (26%) 
 
34 (27%) 
33 (26%) 
27 (21%) 
33 (26%) 
Years of education 14·0 ± 3·5 14·6 ± 4·2 
MIRS – median, ranges 3 (1 to 5) 3 (1 to 5) 
Use of walking aids – no. (%) 
- Walking with aids† 
- Intermittent use of wheelchair† 
 
23 (18%) 
18 (114%) 
 
25 (20%) 
20 (16%) 
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CIS-fatigue 44·9 ± 5·92 44·9 ± 6·3 
BDI-FS 4·3 ± 3·1 4·0 ± 3·2 
Involvement of caregiver† – no. (%) 56 (44%) 50 (39%) 
Employment – no. (%) 46 (36%) 49 (39%) 
Concomitant condition and therapy 
Presence of cardiac condition – no. (%) 
- Cardiac condition – not further specified 
- Cardiac arrhythmia or conduction defect 
- Cardiomyopathy 
 
  6 (5%) 
37 (30%) 
  3 (2%) 
 
  2 (2%) 
41 (33%) 
  3 (2%) 
Presence of pacemaker and/or ICD – no. (%) 23 (18%) 21 (17%) 
Regular use of assistive ventilatory device – 
no. (%) 
 
23 (18%) 
 
16 (13%) 
Medication – no. (%) 
- Psychostimulant drug use (total) 
- Modafanil 
- Ritalin  
- Antidepressants 
 
25 (20%) 
20 (16%) 
2 (2%) 
3 (2%) 
 
25 (20%) 
19 (15%) 
1 (1%) 
5 (4%) 
Genetics 
Estimated progenitor CTG repeat length – 
median (range) 
 
233·0 (50 to 789) 
 
211·5 (61 to 726) 
Modal CTG repeat length – mean, median   
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(SD) 508·9, 482·0 ± 276·1 512·3, 470·0 ± 292·2 
 
Table 1. Characteristics of patients at study entry  
* Plus-minus values are observed means ± SD.  
† one missing value for walking with aids, intermittent wheelchair use, involvement of the caregiver.  
Abbreviations: BMI: body mass index, MIRS: muscular impairment rating scale, CIS-fatigue: checklist 
individual strength, subscale fatigue, BDI-FS: Beck depression inventory fast-screen, ICD: implantable 
cardioverter-defibrillator  
 Okkersen 23 
 
 
 
Table 2. Changes in primary and secondary outcomes between baseline and 10 months 
 
 Intervention group (N=128) Standard care group (N=127) Mean (95%CI) difference between 
groups 
 N Mean (SD) 
Unadjusted 
Mean change 
(95%CI) from 
baseline 
Adjusted* 
N Mean (SD) 
Unadjusted 
Mean change 
(95%CI) from 
baseline 
Adjusted* 
Adjusted* p-value 
Primary Outcome 
DM1-Activ-c score [higher is beneficial] 
Baseline 128 61·22 (17·35)  127 63·00 (17·35)    
10 months 115 63·92 (17·41) 1·53 (-0·14 to 3·20) 116 60·79 (18·49) -2·02 (-4·02 to -0·01) 3·27 (0·93 to 
5·62) 
0·007 
Secondary Outcomes∫ 
Total distance (m) in 6 MWT [higher is beneficial]; end-of-test BORG score [lower is beneficial]& 
Baseline 
6MWT 
 
128  
389·29 (123·20) 
 
 127  
400·69 (119·74) 
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BORG 4·56 (2·28) 4·58 (2·14) 
10 months 
6MWT 
 
 
BORG 
111  
420·65 (134·84) 
 
 
4·22 (2·01) 
 
22·61 (10·60 to 
34·61) 
 
-0·21 (-0·59 to 
1·76) 
 
99  
401·10 (133·49) 
 
 
4·60 (2·05) 
 
-4·39 (-14·49 to 
5·72) 
 
0·235 ( -0·17 to 1·79) 
 
26·5 (11·1 to 
41·8) 
 
-0·42 (-0·89 to 
0·06) 
 
0·0009 
 
 
0·083 
 
MDHI score [lower is beneficial] 
Baseline 128 37·49 (18·33)  127 35·64 (16·08)    
10 months 112 31·78 (19·35) -5·30 (-7·44 to -
3·15) 
106 33·05 (17·72) -2·07 (-4·36 to 0·22) -2·35 ( -5·35 to 
0.65) 
0·126 
Accelerometry (ENMO) - Mean (24h) physical activity† [higher is beneficial] 
Baseline 128 19·92 (9·53)  127 21·33 (12·72)    
10 months 88 21·22 (9·91) 0·977 (-0·292 to 
2·247) 
76 19·32 (8·85) -2·192 (-3·831 to -
0·554) 
3·23 (1·47 to 
5·00) 
0·0005 
Accelerometry (ENMO) - Mean (most active 5 hours) physical activity† [higher is beneficial] 
Baseline 128 48·80 (26·19)  127 51·01 (34·56)    
10 months 88 53·60 (29·93) 3·439 (-0·897 to 76 47·21 (24·93) -3·897 (-8·366 to 8·36 (2·62 to 0·005 
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7·776) 0·572) 14·10) 
Accelerometry (ENMO) - Mean (least active 5 hours) physical activity† 
Baseline 128 3·86 (0·79)  127 4·29 (2·38)    
10 months 88 3·88 (0·78) 0·038 (-0·142 to 
0·217) 
76 3·80 (0·66) -0·541 (-1·154 to 
0·073) 
0·181 (-0·059 to 
0·422) 
0·141 
FDSS score [lower is beneficial] 
Baseline 128 45·87 (9·72)  126 46·52 (11·54)    
10 months 109 38·38 (10·27) -7·44 (-9·20 to -
5·68) 
104 43·22 (10·78) -3·50 (-5·16 to -1·84) -4·15 (-6.30 to -
2.00) 
0·0002 
CIS-fatigue score [lower is beneficial] 
Baseline 128 44·89 (5·92)  127 44·88 (6·34)    
10 months 113 36·27 (10·91) -8·38 (-10·29 to -
6·46) 
106 40·62 (8·46) -4·34 (-5·82 to -2·85) -3·93 (-1·58 to -
6·28) 
0·001 
InQoL – QoL domain score [lower is beneficial] 
Baseline 128 78·14 (31·94)  127 72·72 (34·82)    
10 months 113 69·21 (35·95) 
 
-8·15 (-12·96 to -
3·34) 
105 70·26 (34·80) -2·27 (-8·00 to 3·47) -4·52 (-11·35 to 
2·31) 
0·196 
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BDI-FS‡ score [lower is beneficial] 
Baseline 128 4·31 (3·10)  127 4·03 (3·15)    
10 months 110 4·06 (3·44) -0·330 (-0·91 to 
0·241) 
105 3·60 (3·14) -0·277 (-0·794 to 
0·240) 
0·064 (-0·644 to 
0·772) 
0·859 
AES-c score [lower is beneficial] 
Baseline 128 38·87 (9·07)  127 37·33 (8·65)    
10 months 109 36·31 (8·47) 0·74 (-0·57 to 2·04) 103 37·24 (9·84) -0·41 (-1·73 to 0·90) 0·63 (-0·98 to 
2·25) 
0·444 
Stroop interference score‡ [lower is beneficial] 
Baseline 128 92·19 (72·26)  127 90·27 (51·99)    
10 months 115 73·95 (40·15) -16·093 (-26·815 to 
-5·370) 
105 77·75 (51·41) -9·995 (-17·127 to -
2·863) 
-0·035 (-0·115 
to 0·045) 
0·389 
 
Table 2. Changes in Primary and secondary outcomes between baseline and 10 months 
* Adjusted for baseline value, MIRS, site, caregiver involvement and age.  
† As measured with accelerometry – unit measure total ENMO.  
‡ Log-transformed in mixed model.  
∫ Abbreviations: 6MWT: six-minute walk test; AES-c: apathy evaluation scale, clinician version; BDS-FS: Beck depression inventory – fast screen; CIS: 
checklist individual strength; FDSS: fatigue and daytime sleepiness scale; InQoL: individualized neuromuscular quality of life; MDHI: myotonic dystrophy 
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health index – total score; Stroop interference: Stroop color-word interference test 
& 0-10 BORG scale 
For score range as outcome measures, please refer to supplemental table S5. 
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Table 3. Adverse events 
 
SOC classification Intervention group 
N = 128 
Standard care 
Group 
N = 127 
All patients 
N = 255 
Blood and lymphatics 0 [0] 2 [2] 2 [2] 
Cardiac 4 [4] 2 [2] 6 [6] 
Ear and labyrinth 0 [0] 1 [1] 1 [1] 
Eye disorders 1 [1] 1 [1] 2 [2] 
Gastro-intestinal 7 [5] 3 [3] 10 [8] 
General disorders 6 [6] 6 [6] 12 [12] 
Immune system 0 [0] 1 [1] 1 [1] 
Infections and infestations 32 [24] 19 [15] 51 [39] 
Injury, poisoning and procedural 
complications 
- Falls 
162 [46] 
 
155 [40] 
81 [39] 
 
71 [33] 
243 [85] 
 
226 [73] 
Investigations 1 [1] 1 [1] 2 [2] 
Metabolism and nutrition 1 [1] 0 [0] 1 [1] 
Muskuloskeletal and connective 
tissue 
14 [14] 12 [9] 26 [23] 
Neoplasm 1 [1] 0 [0] 1 [1] 
Nervous system 7 [7] 9 [8] 16 [15] 
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Psychiatric 0 [0] 2 [2] 2 [2] 
Reproductive system and breast 1 [1] 0 [0] 1 [1] 
Respiratory thoracic mediastinal 5 [5] 12 [9] 17 [14] 
Skin subcutaneous 1 [1] 0 [0] 1 [1] 
Vascular disorders 1 [1] 3 [3] 4 [4] 
Total number of events 244 [65] 155 [63] 399 [128] 
Table 3. Adverse events 
Adverse events were classified according to System Organ Class (SOC) adverse event terminology.15 
Non occurring AE from the SOC list are not listed. Listed are the numbers of AE that occurred, 
followed by the number of patients in whom these occurred in brackets. 
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Table 4. Serious adverse events 
 Intervention group 
(N = 128) 
Standard care group 
(N = 127) 
All patients 
(N = 255) 
Total falls 5 [5] 1 [1] 6 [6] 
Fall 1 [1] 0 [0] 1 [1] 
Fall with fracture 
(extremity) 
1 [1] 0 [0] 1 [1] 
Fall with suspected or 
actual cranial trauma 
3 [3] 1 [1] 4 [4] 
Total pulmonary and 
non-cardiac chest 
5 [5] 5 [5] 10 [10] 
Pneumonia 3 [3] 3 [3] 6 [6] 
Chest Infection 1 [1] 0 [0] 1 [1] 
Pulmonary embolism 0 [0] 2 [2] 2 [2] 
Pneumothorax 1 [1] 0 [0] 1 [1] 
Total cardiac 5 [4] 6 [4] 11 [8] 
Myocardial infarction 1 [1] 2 [2] 3 [3] 
Cardiac arrest 1 [1] 0 [0] 1 [1] 
Atypical chest 
complaints 
2 [2] 1 [1] 3 [3] 
Tachycardia 0 [0] 2 [1] 2 [1] 
Arrhythmia 1 [1] 0 [0] 1 [1] 
Pacemaker installation 0 [0] 1 [1] 1 [1] 
Total gastro-
intestinal  
6 [5] 5 [3] 11 [8] 
Constipation 0 [0] 2 [1] 2 [1] 
Dysphagia 0 [0] 1 [1] 1 [1] 
Gallstone attack 1 [1] 1 [1] 2 [2] 
Bile cystitis 1 [1] 0 [0] 1 [1] 
Peptic Ulcer 0 [0] 1 [1] 1 [1] 
Volvulus 1 [1] 0 [0] 1 [1] 
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GI malignancy (liver) 1 [1] 0 [0] 1 [1] 
Ulcerative colitis 1 [1] 0 [0] 1 [1] 
Abdominal pain – 
unknown etiology 
1 [1] 0 [0] 1 [1] 
Total other 3 [3] 6 [5] 9 [8] 
Extremity fracture – not 
related to falls 
1 [1] 1 [1] 2 [2] 
Urinary tract infection 0 [0] 1 [1] 1 [1] 
Vertigo 0 [0] 1 [1] 1 [1] 
Headache of severe 
intensity 
0 [0] 1 [1] 1 [1] 
Leg pain – unknown 
etiology 
0 [0] 1 [1] 1 [1] 
Back pain - lumbago 1 [1] 0 [0]  1 [1] 
(Epileptic) seizure 1 [1] 0 [0] 1 [1] 
Wound dehiscence 0 [0] 1 [1] 1 [1] 
Overall Total SAE 24 [19] 23 [15] 47 [34] 
Table 4. Serious adverse events 
Number of adverse events and serious adverse events occurring up to 14 days after the final visit (16 
months after baseline), followed by number of patients in whom these occurred in brackets. The 
number in brackets do not always sum up to the totals presented as a consequence of some patients 
that had multiple SAE.  
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